Manganese superoxide dismutase (MnSOD) gene polymorphism, interactions with carotenoid levels and prostate cancer risk.
BACKGROUND
The manganese superoxide dismutase (MnSOD) gene encodes an antioxidant enzyme (SOD2) that may protect cells from oxidative damage. The MnSOD allele with Val as amino acid 16 encodes a protein that has 30-40% lower activity compared with the MnSOD Ala variant, hence possibly increasing susceptibility to oxidative stress. On the other hand, some epidemiologic studies suggest that the Ala allele is associated with a higher risk of cancer, including prostate cancer.


METHODS
We conducted a nested case-control study in the Health Professionals Follow-up Study with 612 incident prostate cancer cases and 612 matched controls to investigate the role of the MnSOD gene Ala16Val polymorphism and its joint association with plasma carotenoid concentrations in relation to risk of total prostate cancer and aggressive prostate cancer (advanced stage or Gleason sum > or =7).


RESULTS
The allele frequencies in the controls were 49.8% for Ala and 50.2% for Val. No association was found between the MnSOD genotype and risk of total and aggressive prostate cancer. Furthermore, no statistically significant interaction was observed between the MnSOD genotype and any of the plasma carotenoids in relation to risk of total and aggressive prostate cancer. In analyses in which we combined data from plasma and dietary carotenoids and created a quintile score to reflect long-term carotenoid status, a 3-fold [95% confidence interval: 1.37-7.02] increased risk of aggressive prostate cancer was observed among men with the Ala/Ala genotype in the presence of low long-term lycopene status (P-value, test for interaction = 0.02) as compared with men with the Ala/Val+Val/Val genotypes with low long-term lycopene status.


CONCLUSIONS
In this cohort of mainly white men, the MnSOD gene Ala16Val polymorphism was not associated with total or aggressive prostate cancer risk. However, men with the MnSOD Ala/Ala genotype who had low long-term lycopene status had a higher risk of aggressive prostate cancer compared with individuals with the other genotypes. These results are consistent with findings from earlier studies that reported when antioxidant status is low, the MnSOD Ala/Ala genotype may be associated with an increased risk of aggressive prostate cancer.
Mikhak
Bahar
B
Department of Epidemiology, Harvard School of Public Health, Boston, MA 02115, USA.
Hunter
David J
DJ
Spiegelman
Donna
D
Platz
Elizabeth A
EA
Wu
Kana
K
Erdman
John W
JW
Giovannucci
Edward
E
D000368:Aged; D002338:Carotenoids / Q000097:blood*; D016022:Case-Control Studies; D004032:Diet; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D020641:Polymorphism, Single Nucleotide; D011471:Prostatic Neoplasms / Q000097:blood* / Q000235:genetics* / Q000473:pathology; D012307:Risk Factors; D013482:Superoxide Dismutase / Q000235:genetics*; D011795:Surveys and Questionnaires
D002338:Carotenoids; D013482:Superoxide Dismutase
Pharmacogenetics. 2003 Mar;13(3):145-57
12618592
Cancer Epidemiol Biomarkers Prev. 2007 Jun;16(6):1115-20
17548672
Ann N Y Acad Sci. 1998 Nov 20;854:443-7
9928451
J Clin Invest. 1986 Apr;77(4):1402-4
3457020
DNA Cell Biol. 1994 Nov;13(11):1127-36
7702755
Cancer Res. 1979 Apr;39(4):1141-9
217531
Cancer Res. 1999 Feb 1;59(3):602-6
9973207
Oncogene. 2005 Jan 6;24(1):77-89
15543233
Free Radic Biol Med. 2001 Feb 1;30(3):260-7
11165872
Nat Genet. 1995 Dec;11(4):376-81
7493016
J Nutr. 2003 Jun;133(6):1930-6
12771341
J Nutr. 2001 Jun;131(6):1746-52
11385062
Biochim Biophys Acta. 1995 May 24;1271(1):205-9
7599209
J Chronic Dis. 1984;37(2):137-42
6693532
Cancer Causes Control. 2003 Aug;14(6):513-8
12948282
Cancer Epidemiol Biomarkers Prev. 2007 Aug;16(8):1581-6
17646272
Cancer Epidemiol Biomarkers Prev. 2004 Mar;13(3):340-5
15006906
Am J Clin Nutr. 1983 Oct;38(4):631-9
6624705
Cancer Res. 2005 Mar 15;65(6):2498-504
15781667
Carcinogenesis. 2006 Jun;27(6):1187-93
16364923
Am J Clin Nutr. 1996 Oct;64(4):594-602
8839505
J Chronic Dis. 1984;37(2):125-36
6693531
Prostate. 1998 May 15;35(3):221-33
9582091
Biochem Biophys Res Commun. 1996 Sep 13;226(2):561-5
8806673
Free Radic Biol Med. 2004 Mar 15;36(6):718-44
14990352
Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):260-9
14973107
Oncogene. 1997 Jan 30;14(4):481-90
9053845
Prostate. 1997 Sep 1;32(4):229-33
9288180
Am J Epidemiol. 1992 May 15;135(10):1114-26; discussion 1127-36
1632423
Proc Natl Acad Sci U S A. 1991 Aug 15;88(16):7276-80
1871133
Rev Epidemiol Sante Publique. 1990;38(1):41-6
2181566
Free Radic Res. 2004 Oct;38(10):1119-32
15512801
Pharmacogenet Genomics. 2005 May;15(5):311-9
15864132
Proc Natl Acad Sci U S A. 1996 Apr 30;93(9):4471-3
8633092
J Natl Cancer Inst. 2002 Mar 6;94(5):391-8
11880478
Cell Growth Differ. 1996 Sep;7(9):1175-86
8877099
Antioxid Redox Signal. 2004 Jun;6(3):483-7
15130275